Yokohama Japan, 16 May 2022: We are pleased to announce that the Clinical Phase II Trial of Stemchymal, a regenerative medicine product derived from somatic stem cells, has been completed in Japan. Previously, on 24 May 2021, we announced that administrations of Stemchymal had been completed for all patients enrolled for the treatment of spinocerebellar ataxia. After data collection, we will unblind the allocation information for the blinded treatment/placebo group (i.e., code-break), conduct data analysis and evaluation, and prepare for submission for approval.
We will endeavor to obtain clinical approval as soon as possible so that we can provide the new treatment to patients suffering from this disease.
